Importantly, recent studies demonstrated that the expression level of CSCs markers such as CD44, CD133, CD166, Nanog, Oct-4, and ALDH1 are promising prognostic markers that can predict the clinicopathological features in CRC patients [14–19]. This evidence concerns the gene CD44 and colorectal carcinoma.